SLS

Galena生物制药
NASDAQ

实时行情|Nasdaq Last Sale

1.610
+0.010
+0.63%
交易中 15:26 04/02 EDT
开盘
1.550
昨收
1.600
最高
1.700
最低
1.550
成交量
7.12万
成交额
--
52周最高
61.50
52周最低
1.530
市值
1,081.58万
市盈率(TTM)
-0.0743
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SLS价格均价为8.50,最高价位9.00,最低价为8.00。

EPS

SLS 新闻

更多
  • 瑞幸爆出财务造假丑闻 股价一度狂跌八成
  • 新浪美股 · 48分钟前
  • 特朗普称沙特和俄罗斯同意减产约1000万桶 但消息未获沙特证实
  • 新浪美股 · 1小时前
  • 特朗普宣称石油减产遭“打脸” 油价经历过山车行情
  • 新浪财经-自媒体综合 · 1小时前
  • 午后:油价大起大落 美股涨幅收窄
  • 新浪美股 · 1小时前

所属板块

制药
+1.52%
制药与医学研究
+1.54%

热门股票

代码
价格
涨跌幅

SLS 简况

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
展开

微牛提供Sellas Life Sciences Group Inc(NASDAQ-SLS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SLS股票新闻,以帮助您做出投资决策。